Multicenter clinical trial of intravenous OvaRex MAb-B43.13 as post-chemotherapy consolidation for ovarian carcinoma
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2007
At a glance
- Drugs Oregovomab (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 17 Dec 2007 Status change from in progress to discontinued. This study was closed by the sponsor.
- 31 Jul 2006 Status change
- 25 Sep 2005 New trial record.